Autopsy report · NCT03601819

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

“Low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 1 year 2 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

University of Michigan Rogel Cancer Center

Sponsor type

University, hospital or other

Conditions

Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Chronic Lymphocytic Leukemia; Lymphoproliferative Disorders; Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma

Interventions

Pacritinib

Participants

4

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.